Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferri, C.
Right arrow Articles by De Mattia, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferri, C.
Right arrow Articles by De Mattia, G.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 18, Issue 2 226-233, Copyright © 1995 by American Diabetes Association


ARTICLES

Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic clamp in lean NIDDM men

C Ferri, A Carlomagno, S Coassin, R Baldoncini, MR Cassone Faldetta, O Laurenti, G Properzi, A Santucci and G De Mattia
Istituto di I Clinica Medica, Universita La Sapienza, Rome, Italy.

OBJECTIVE--To evaluate whether or not insulin stimulates endothelin (ET)-1 secretion in vivo. RESEARCH DESIGN AND METHODS--Plasma ET-1 levels were evaluated in 16 lean normotensive men with non-insulin-dependent diabetes mellitus (NIDDM) (mean age 50.3 +/- 4.1 years) during either a 2-h euglycemic hyperinsulinemic clamp (40 mU insulin.m-2.min-1) or placebo infusion (50 ml isotonic saline) according to a single-blind randomized crossover protocol. RESULTS--Circulating ET-1 levels increased during the euglycemic hyperinsulinemic clamp (from 0.88 +/- 0.38 pg/ml at time 0 to 1.66 +/- 0.22 pg/ml and 1.89 +/- 0.99 pg/ml at 60 and 120 min, respectively [P < 0.05 vs. time 0]) and returned to baseline levels after the discontinuation of insulin infusion (0.71 +/- 0.22 pg/ml after a 30-min period of recovery [NS]). Compared with placebo, the euglycemic hyperinsulinemic clamp induced a significant increase in plasma ET-1 levels at 60 min (P < 0.0001) and 120 min (P < 0.0001). Changes in basal insulin levels and corresponding changes in circulating ET-1 levels after a 2-h euglycemic hyperinsulinemic clamp were significantly correlated (r = 0.771, P < 0.0001). A possible unfavorable effect of ET-1 on the tissue sensitivity to insulin-stimulated glucose uptake was suggested by the presence of a negative correlation between total glucose uptake and baseline ET-1 levels (r = -0.498, P < 0.05). CONCLUSIONS--Our findings indicate that circulating ET-1 levels significantly increase during euglycemic hyperinsulinemic clamp in men with NIDDM. The negative correlation between total glucose uptake and circulating ET-1 levels suggests that the peptide might exert negative effects on the insulin sensitivity of target tissues. The consequent increase in insulin secretion as well as the insulin-related ET-1 release from endothelial cells could favor the development of diabetes-related vascular lesions.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. A. Lteif, A. D. Fulford, R. V. Considine, I. Gelfand, A. D. Baron, and K. J. Mather
Hyperinsulinemia fails to augment ET-1 action in the skeletal muscle vascular bed in vivo in humans
Am J Physiol Endocrinol Metab, December 1, 2008; 295(6): E1510 - E1517.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. G. Clark
Impaired microvascular perfusion: a consequence of vascular dysfunction and a potential cause of insulin resistance in muscle
Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E732 - E750.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
E. C. Eringa, C. D. A. Stehouwer, M. H. Roos, N. Westerhof, and P. Sipkema
Selective resistance to vasoactive effects of insulin in muscle resistance arteries of obese Zucker (fa/fa) rats
Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1134 - E1139.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon
Cardiovascular Actions of Insulin
Endocr. Rev., August 1, 2007; 28(5): 463 - 491.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
G. Ahlborg, A. Shemyakin, F. Bohm, A. Gonon, and J. Pernow
Dual Endothelin Receptor Blockade Acutely Improves Insulin Sensitivity in Obese Patients With Insulin Resistance and Coronary Artery Disease
Diabetes Care, March 1, 2007; 30(3): 591 - 596.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. A. Sarafidis and G. L. Bakris
Insulin and Endothelin: An Interplay Contributing to Hypertension Development?
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 379 - 385.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
R. Kelly, T. Ruane-O'Hora, M. I. M. Noble, A. J. Drake-Holland, and H. M. Snow
Differential inhibition by hyperglycaemia of shear stress- but not acetylcholine-mediated dilatation in the iliac artery of the anaesthetized pig
J. Physiol., May 15, 2006; 573(1): 133 - 145.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. S. Hermann, W. Li, H. Dominguez, N. Ihlemann, C. Rask-Madsen, A. Major-Pedersen, D. B. Nielsen, K. W. Hansen, M. Hawkins, L. Kober, et al.
Quinapril Treatment Increases Insulin-Stimulated Endothelial Function and Adiponectin Gene Expression in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1001 - 1008.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
E. C. Eringa, C. D. A. Stehouwer, K. Walburg, A. D. Clark, G. P. van Nieuw Amerongen, N. Westerhof, and P. Sipkema
Physiological Concentrations of Insulin Induce Endothelin-Dependent Vasoconstriction of Skeletal Muscle Resistance Arteries in the Presence of Tumor Necrosis Factor-{alpha} Dependence on c-Jun N-Terminal Kinase
Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 274 - 280.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. C. Eringa, C. D. A. Stehouwer, G. P. van Nieuw Amerongen, L. Ouwehand, N. Westerhof, and P. Sipkema
Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium
Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2043 - H2048.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Rab, S. Dallinger, K. Polak, J. Pleiner, E. Polska, M. Wolzt, and L. Schmetterer
Specific Endothelin ETA Receptor Antagonism Does Not Modulate Insulin-Induced Hemodynamic Effects in the Human Kidney, Eye, or Forearm
J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 692 - 696.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Tardif, N. Julien, A. Pelletier, G. Thibault, A. K. Srivastava, J.-L. Chiasson, and L. Coderre
Chronic exposure to beta -hydroxybutyrate impairs insulin action in primary cultures of adult cardiomyocytes
Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1205 - E1212.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Diamanti-Kandarakis, G. Spina, C. Kouli, and I. Migdalis
Increased Endothelin-1 Levels in Women with Polycystic Ovary Syndrome and the Beneficial Effect of Metformin Therapy
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4666 - 4673.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
R.J. Irving, J.P. Noon, G.C.M. Watt, D.J. Webb, and B.R. Walker
Activation of the endothelin system in insulin resistance
QJM, June 1, 2001; 94(6): 321 - 326.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. Calles-Escandon and M. Cipolla
Diabetes and Endothelial Dysfunction: A Clinical Perspective
Endocr. Rev., February 1, 2001; 22(1): 36 - 52.
[Abstract] [Full Text]


Home page
CirculationHome page
G. Desideri, A. Gaspardone, M. Gentile, A. Santucci, P. A. Gioffre, and C. Ferri
Endothelial Activation in Patients With Cardiac Syndrome X
Circulation, November 7, 2000; 102(19): 2359 - 2364.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Ferri, C. Bellini, G. Desideri, E. Giuliani, L. De Siati, S. Cicogna, and A. Santucci
Clustering of Endothelial Markers of Vascular Damage in Human Salt-Sensitive Hypertension : Influence of Dietary Sodium Load and Depletion
Hypertension, November 1, 1998; 32(5): 862 - 868.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. J Rabelink, E. S.G Stroes, K.P. Bouter, and P. Morrison
Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?
Cardiovasc Res, September 1, 1998; 39(3): 543 - 549.
[Full Text] [PDF]


Home page
HypertensionHome page
P. Nava Maria, T. Collados, F. Masso, and V. Guarner
Endothelin Mediation of Insulin and Glucose-Induced Changes in Vascular Contractility
Hypertension, October 1, 1997; 30(4): 825 - 829.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
Z. K. Krowicki, N. A. Nathan, and P. J. Hornby
Excitatory Gastric Motor and Cardiovascular Effects of Endothelins in the Dorsal Vagal Complex are Mediated Through ETA Receptors
J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 535 - 542.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1995 by the American Diabetes Association.